Clinical trials examine COVID-19 rebound after nirmatrelvir/ritonavir versus placebo treatment

A summary of randomized, double-blind clinical trials conducted at sites in the United States and internationally examined the occurrence of COVID-19 rebound following treatment. The intervention studied was nirmatrelvir/ritonavir, compared against a placebo. No specific results were reported for the primary outcome, secondary outcomes, or main results, including effect sizes, absolute numbers, or statistical measures. The population studied, sample size, and duration of follow-up were also not reported.

No safety or tolerability data were provided, including rates of adverse events, serious adverse events, or treatment discontinuations. The summary did not list specific methodological limitations of the trials. Information regarding funding sources or potential conflicts of interest was not reported.

Given the absence of reported results, the practice relevance of these trials for managing COVID-19 rebound cannot be determined. Clinicians should seek the full, peer-reviewed publication of these trials for detailed efficacy and safety data before drawing any conclusions about the relationship between nirmatrelvir/ritonavir and COVID-19 symptom rebound.